Nodes Logo

Pinetree Therapeutics

Bispecific antibody platform Massachusetts, USA

| Overview |

Pinetree Therapeutics has developed a disruptive bispecific antibody platform targeting previously difficult-to-engage oncology targets and a novel recombinant therapeutic platform applicable to a broad spectrum of infectious diseases.

Sector

Therapeutics

Round

Series A2

Transaction

Capital Raise

Transaction Value

Undiscolosed

Space

Bispecific antibody platforms for oncology and infectious diseases

Milestones

  • Founded in 2019
  • Emerged from stealth in 2022

Investors

InterVest

SK Securities

DSC Investment

SJ Investment Partners

Founders

Ho-Juhn Song

Challenge

Acquired resistances cause many cancer and infectious disease treatments to fail

Acquired resistances cause many cancer and infectious disease treatments to fail due to the resilience of target proteins and reliance on non-highly conserved disease targets.

Solution

TAER-TAB™ & ViTRAP

Pinetree Therapeutics has two main technologies TAER-TAB™ (Tumor Associated Essential Receptor Targeting Antibodies) and ViTRAP (Virus Targeting Recombinant Agent) which promote disease-specific target protein degradation and allow for targeting of highly-conserved disease targets.

Impact

Around $27B market

Pinetree Therapeutics is targeting multiple large markets, such as the non-small cell lung cancer market which has been estimated to be ~$27B in 2022.

“Our approaches range from the degradation of drug resistant-oncogenic and immuno-oncology receptors, in situ cancer vaccination, to even anti-viral infection therapeutics, which is one of a kind and has never been tried before.”

Ho-Juhn Song (Founder)

Get in touch

Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.